Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

Barry Bresnihan, Jos� Maria Alvaro-Gracia, Mark Cobby et al. · Arthritis & Rheumatism · 1998 · 974 citations

Medicine, Immunology, Pharmacotherapy +16

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

Thierry Lequerré, Pierre Quartier, David Rosellini et al. · Annals of the Rheumatic Diseases · 2007 · 404 citations · Full text

Medicine, Pediatrics, Pharmacotherapy +11

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

Stanley Cohen · Annals of the Rheumatic Diseases · 2004 · 301 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers

Piero Ruscitti, Paola Cipriani, Francesco Masedu et al. · BMC Medicine · 2016 · 176 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey

Linda Rossi‐Semerano, Bruno Fautrel, Daniel Wendling et al. · Orphanet Journal of Rare Diseases · 2015 · 133 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +16